These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
36. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy. Zhou LT; Liu FY; Li Y; Peng YM; Liu YH; Li J Neoplasma; 2012; 59(1):1-5. PubMed ID: 22017590 [TBL] [Abstract][Full Text] [Related]
37. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads. Ojima I Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526 [TBL] [Abstract][Full Text] [Related]
38. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. Mascelli MA; Zhou H; Sweet R; Getsy J; Davis HM; Graham M; Abernethy D J Clin Pharmacol; 2007 May; 47(5):553-65. PubMed ID: 17379759 [TBL] [Abstract][Full Text] [Related]
39. Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids. Hamilton GS Biologicals; 2015 Sep; 43(5):318-32. PubMed ID: 26115630 [TBL] [Abstract][Full Text] [Related]
40. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts. Mazor Y; Noy R; Wels WS; Benhar I Cancer Lett; 2007 Nov; 257(1):124-35. PubMed ID: 17698286 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]